Loading…
Back To Schedule
Tuesday, September 20 • 9:45am - 10:30am
Panel: Leverage AI and ML to Advance Discovery and Accelerate Drug Development

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Developing a therapeutic on average takes 12+ years and billions of dollars, but now with AI and machine learning, the potential to identify molecules and bring them to the clinic faster and cheaper can be a reality. But where has there been proven success applying AI and ML and does it live up to the hype?
Moderator
avatar for Yaron Turpaz, Ph.D.

Yaron Turpaz, Ph.D.

Senior Vice President and Senior Advisor, Computational Discovery, Compugen
Dr. Turpaz is an SVP & Sr. Advisor, Computational Discovery at Compugen. Dr. Turpaz has more than 15 years of experience in the fields of R&D informatics, data sciences and technology in the biotech and pharma space with hands-on experience using cloud-based high throughput computational... Read More →

Speakers
avatar for Jane Rhodes, PhD, MBA

Jane Rhodes, PhD, MBA

Chief Business Officer, Verge Genomics
Jane Rhodes, PhD, MBA is Chief Business Officer at Verge Genomics. Jane brings more than 25 years of drug discovery, company building and strategic leadership in the biotech industry, including 18 years at Biogen. Jane’s passion lies at the intersection of technology and life science... Read More →
avatar for Frank D. Yocca, Ph.D.

Frank D. Yocca, Ph.D.

Senior Vice President & Chief Scientific Officer, BioXcel Therapeutics
Dr. Yocca is an accomplished R&D executive and scientist with extensive experience leading global biopharmaceutical companies. He has wide-ranging expertise in leading high performance, world-class teams in drug discovery and development whose efforts have resulted in a number of... Read More →
avatar for Andrew A. Radin

Andrew A. Radin

Co-founder and CEO, Aria Pharmaceuticals
Andrew A. Radin is the co-founder and Chief Executive Officer of Aria Pharmaceuticals. Andrew created the company’s first drug development algorithms as part of his studies in biomedical informatics at Stanford University in 2014. Since co-founding Aria, Andrew was named an Emerging... Read More →
avatar for Molly Gibson, Ph.D

Molly Gibson, Ph.D

Co-founder, Chief Strategy and Chief Innovation Officer, Generate Biomedicines
Molly serves as co-founder and chief strategy and chief innovation officer of Generate Biomedicines, a Flagship Pioneering company. At Generate, she oversees corporate strategy, platform and data strategy, and an innovation group called G:Labs that explores novel applications of the... Read More →

Tuesday September 20, 2022 9:45am - 10:30am EDT
  General Session